Get the Stockscreener App
162.80
2.09%
-3.48
Belite Bio Inc Adr stock is traded at $162.80, with a volume of 228.79K.
It is down -2.09% in the last 24 hours and up +10.99% over the past month.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
See More
Previous Close:
$166.28
Open:
$166.51
24h Volume:
228.79K
Relative Volume:
1.10
Market Cap:
$6.53B
Revenue:
-
Net Income/Loss:
$-77.61M
P/E Ratio:
-70.85
EPS:
-2.2979
Net Cash Flow:
-
1W Performance:
-0.15%
1M Performance:
+10.99%
6M Performance:
-7.11%
1Y Performance:
+136.01%
1-Day Range:
$159.00
$167.00
1-Week Range:
$159.00
$181.56
52-Week Range:
$60.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
162.80 | 7.17B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio CFO Hao-Yuan Chuang Sells 367 ADS Under Rule 10b5-1 Plan - Kalkine Media
Belite Bio CEO Lin Yu-Hsin Reports Sale of 365 ADS Under Rule 10b5-1 Plan - Kalkine Media
Benchmark reiterates Belite Bio stock rating on FDA priority review - Investing.com
Benchmark reiterates Belite Bio stock rating on FDA priority review By Investing.com - Investing.com Canada
Mizuho raises Belite Bio stock price target to $220 on NDA progress - Investing.com
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares By Investing.com - Investing.com South Africa
Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Yu-Hsin Lin Sells 365 Shares of Belite Bio (NASDAQ:BLTE) Stock - MarketBeat
Belite Bio CFO Chuang Hao-Yuan sells $66,187 in shares - Investing.com
Belite Bio CEO Lin Yu-Hsin sells company stock, over $65,000 - Investing.com Nigeria
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... By GuruFocus - Investing.com Canada
Belite Bio Q2 2026 Earnings Call Transcript - MarketBeat
Belite Bio Q2 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips - Investing.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 7.2%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out - TipRanks
Belite Bio (NASDAQ: BLTE) wins FDA Priority Review and reports wider Q2 2026 loss - Stock Titan
Belite Bio (BLTE) Is Up 12.9% After FDA Priority Review For Tinlarebant In Stargardt Disease - Sahm
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times
BLTE (NASDAQ: BLTE) files Form 144 for 93,800 ADS sale - Stock Titan
Yi Chen Raises Approval Odds and Lifts Tinlarebant-Focused 12‑Month Price Target to $214 While Reiterating Buy Rating - TipRanks
Belite Bio stock price target raised to $214 by H.C. Wainwright on FDA review - Investing.com Nigeria
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA - Yahoo Finance
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Belite Bio stock rating on regulatory outlook - Investing.com
HC Wainwright Issues Positive Forecast for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease - TipRanks
FDA grants priority review for Belite Bio’s Stargardt treatment By Investing.com - Investing.com Nigeria
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (NASDAQ: BLTE) wins FDA priority review for tinlarebant in Stargardt disease - Stock Titan
How Belite Bio Inc (BLTE) Affects Rotational Strategy Timing - Stock Traders Daily
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
The Manufacturers Life Insurance Company Purchases New Shares in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results - markets.businessinsider.com
Renaissance Technologies LLC Makes New Investment in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
Belite Bio (BLTE) Expected to Post Quarterly Earnings on Monday - MarketBeat
Perceptive Advisors LLC Has $24.23 Million Stock Position in Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
ADAR1 Capital Management LLC Sells 12,959 Shares of Belite Bio, Inc. Sponsored ADR $BLTE - MarketBeat
(BLTE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Price to sales forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
Belite Bio, Inc. ADR Revenue Breakdown – FWB:D01 - TradingView
Belite Bio, Inc. Sponsored ADR $BLTE Shares Acquired by Affinity Asset Advisors LLC - MarketBeat
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - MarketBeat
Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com UK
Belite Bio stock price target maintained at $200 by H.C. Wainwright By Investing.com - Investing.com Australia
Belite Bio presents additional Phase 3 trial data for tinlarebant By Investing.com - Investing.com South Africa
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1 - The Manila Times
Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com
Belite Bio, Inc. ADR (BLTE) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):